TABLE 1.
Cohorts employed in this studyl
| Sample cohort | No. of individuals | No. of individuals of gender (M/F/NA)a | Age (yrs)b | No. of days after symptom onsetb | No. of days after diagnosisb | Description |
|---|---|---|---|---|---|---|
| Conv | 197 | 126/64/7 | 42 (32–54) | 28 (24–31) | 24 (20–27) | Mild disease, no O2 support |
| Hosp | 27c | 19/8 | 65 (55–73) | 6 (1.5–7)c | 0c | Moderate to severe disease |
| 27d | 13 (10–16)d | 8 (7–9)d | ||||
| Ctrl | 45e | 13/32e | 54 (39–61)e | NAe | NAe | |
| 171f | 53/103/15f | 56 (49–62)f | NAf | NAf | ||
| +Eval | 50 | 34/16 | 63 (53–70) | 17 (16–19) | 11 (6–13) | Moderate to severe disease |
| −Eval | 50 | 24/26 | 26 (16–36) | NA | NA | |
| Conv Follow Up | 34g,h | 23/11g,h | 45 (38–58)g,h | 31 (28–34)g | 38 (30–42)g | Samples collected at 3 time points after symptom onset |
| 31i | 21/10i | 45 (38–59)i | 98 (70–102)h | 101 (73–106)h | ||
| 178 (174–185)i | 182 (178–193)i | |||||
| hCoV | 17j | 9/8j | 66 (46–72)j | NAj | 130 (31–221)j | Swab positive for OC43/HKU1, 229E, or NL63 |
| 5k | 3/2k | 32 (24–37)k | NAk | NAk | ||
M/F/NA, male/female/not available.
Data are presented as medians (interquartile ranges).
Samples collected 0 to 1 day after hospitalization.
Samples collected 6 to 10 days after hospitalization.
Samples collected from 28 to 30 January 2020.
Samples collected from 2007 to 2019.
Draw 1, samples collected ∼30 days after symptom onset, part of a larger convalescent-phase cohort.
Draw 2, samples collected ∼100 days after symptom onset.
Draw 3, samples collected ∼180 days after symptom onset. Not all patients returned for draw 3.
Samples collected in Umeå, Sweden, in 2019 to 2020.
Samples collected in Bronx, NY, in 2020.
Conv, convalescent; Hosp, hospitalized; Ctrl, control; +Eval, positive evaluation; −Eval, negative evaluation; Conv Follow Up, convalescent-phase follow-up; hCoV, human coronavirus.